Published in TB and Outbreaks Week, January 20th, 2004
Scientists in Thailand sought "to determine whether rifampicin influences the pharmacokinetics of enfuvirtide in HIV-1-infected patients."
"In a single-center, open-label, one-sequence crossover, clinical pharmacology study, 12 HIV-1-infected adults received enfuvirtide (90 mg, twice daily) on days one to three and days 11 to 13 (morning dose only on days three and 13) and rifampicin (600 mg, once daily) from days four to 13," explained M.A. Boyd and coauthors working with the HIV Netherlands Australia Thailand Research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week